Creo's devices and technologies are also increasingly being licensed to robotic surgery companies. Two deals have been announced with the largest robotic surgery company, Intuitive, and with CMR Surgical Ltd, a growing UK-based medical robotics company.
Tiziana Life Sciences has announced that it plans to take foralumab, its fully human anti-CD3 monoclonal, into a clinical study in Alzheimer's disease.
October 2022 marks 25 years since the initial public offering (IPO) of Eurofins Scientific on the Paris stock exchange on October 24 1997. According to this commissioned study, Eurofins has delivered a remarkable total shareholder return (including both share price growth and reinvestment of dividends) of about 36,600% since its IPO.
Open Orphan (hVIVO) is a leader in human respiratory disease and infectious disease challenge clinical studies. It has reported in the H1FY22 results revenues of £18.9mln in the first six months of the year at an EBITDA margin of 12.1%. EBITDA was £2.3mln for the period.
Creo Medical released interim FY22 results in early September following the August trading update. Sales in H1 were £13.6mln. Creo core technology rose to £900k from £200k in the preceding half (H2 FY21) with a doubling of devices used in procedures.
Shield Therapeutics reported H1FY22 sales and royalties of £2mln from its fully approved, patented, oral iron product, Accrufer. Sales of £1.2mln were from the growing US market with a further £0.7mln in Norgine royalties, the European licensee.
In August, Creo released an H1 trading update ahead of the release of the full unaudited H1FY22 results due in September. Creo expects to report a halfon-half increase in revenue of over 10%, from £12.2mln in H2FY21 to around £13.5mln in H1FY22.
MGC Pharmaceuticals Ltd sells plant-derived, medicinal products in the UK, Ireland and Australia. Core marketed products are a food supplement, ArtemiC, to help overcome COVID-19 infection and medicinal cannabis products.
Oxford Cannabinoid Technologies have two lead products OCT461201 (“201”), an oral product to relieve peripheral nerve pain caused by cancer chemotherapy and OCT130401 (“401”), a fast relief inhaled therapy for a sudden onset, facial-pain condition in late preclinical development.
Poolbeg Pharma is to commence a human challenge trial for its lead molecule POLB 001, a small molecule immunomodulator intended for the treatment of severe influenza, marking delivery against an important commitment made in its IPO a year ago.
Copyright © Analyst Hire | Privacy Policy
Logo design, branding & website by SHARED creative